SHANGHAI BIO-HEART BIOLOGICAL TECHNOLOGY CO., LTD.

Highlights Shanghai Bio-heart Biological Technology Co., Ltd.

Equities

2185

CNE100004JH3

Market Closed - Hong Kong S.E. Other stock markets 04:08:09 2024-05-16 EDT			5-day change	1st Jan Change
2.07 ^HKD	+3.50%		+0.98%	-39.47%

03-25	Shanghai Bio-heart Biological Technology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
2023	Shanghai Bio-Heart Biological Technology Co., Ltd. Announces Change of Employee Representative Supervisor	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Shanghai Bio-heart Biological Technology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	03-25	CI
Shanghai Bio-heart Biological Technology's Loss Narrows in H1	23-08-14	MT
Shanghai Bio-heart Biological Technology Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-11	CI
Bioheart Announces Clinical Result for Iberis-Htn At Cit 2023	23-06-29	CI
Shanghai Bio-heart Injects 15 Million Yuan Into Medical Device Developer Xinzhi Medical; Shares Surge 17%	23-04-16	MT
Shanghai Bio-heart Biological Technology Co., Ltd. Announces Achievement of Primary Clinical Endpoint in the Iberis-HTN	23-04-11	CI
Shanghai Bio-heart Biological Technology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-31	CI
Shanghai Bio-heart Biological Technology Co., Ltd. Announces First Patient Enrollment in the RADIUS-HTN Trial	23-03-27	CI
Shanghai Bio-Heart Biological Technology Co., Ltd. Announces Clinical Trial of Sirolimus Drug-Eluting Balloon for the Treatment of In-Stent Restenosis	22-11-17	CI
Shanghai Bio-Heart Biological Technology Co., Ltd. Announces Its Iberis® multi-electrode RDN system product Approve by the Ethics Committee of Ruijin Hainan Hospital	22-11-17	CI
Bio-heart to Infuse $7 Million in Pre-Revenue Medical Device Maker	22-09-06	MT
Bio-Heart Mulls Secondary Listing in Shanghai	22-09-06	MT
Shanghai Bio-Heart Biological Technology Co., Ltd. Announces Achievement of Pre-Set Primary Clinical Endpoint in the RCT of Bioheart Bioresorbable Coronary Rapamycin-Eluting Scaffold in Patients With Coronary Heart Disease	22-08-16	CI
Shanghai Bio-heart Biological Narrows H1 Loss to $17 Million	22-08-08	MT
Chairman to Boost Shanghai Bio-heart Stake	22-08-07	MT
Shanghai Bio-heart Biological Technology Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-05	CI
Shanghai Bio-Heart Biological Technology Co., Ltd. Approves Reappointment of Ernst & Young as Auditor	22-06-27	CI
Bio-heart to Pick Up Over 15% Stake in Pre-Revenue Medical Device Maker	22-06-22	MT
Shanghai Bio-Heart Biological Technology Co., Ltd. Finalizes Plans with Clinical Trial Investigators on the European Clinical Trial on Renal Artery Denervation Using Radial Access in Uncontrolled Hypertension	22-05-19	CI
Bio-Heart Narrows Per-Share Loss in 2021 on Lower R&D Expenses	22-03-21	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Shanghai Bio-heart Biological Technology Co., Ltd.

Equities

2185

CNE100004JH3

Highlights

Filters